CClinicalTrials.gg
Enrolling by invitationNCT05739071Updated Sep 11, 2025

JING SI HERBAL TEA and Urinary Tract Symptoms in Bladder Cancer

An interventional study of JING SI HERBAL TEA and Placebo in Lower Urinary Tract Symptoms, Intravenous Drug Usage and Bladder Cancer, sponsored by Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation. Enrolling by invitation at 1 site in Taiwan. Open to participants aged 20 Years to 100 Years. Per ClinicalTrials.gov, last updated 2025-09-11.

Sponsored by Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
100
Allocation
Randomized
Ages
20 Years to 100 Years
Sex
All
01

Study summary

To identify the effects of JING SI HERBAL TEA in the treatment of lower urinary tract symptoms after intravesical therapy in patients with bladder cancer.

Read the detailed description

The patients with bladder cancer usually required trans urethral resection of bladder tumor (TUR-BT). Post-operative intravesical installation therapy is standard therapy. However, new onset lower urinary tract symptoms often occurred after these installation therapies. JING SI HERBAL TEA is a food contain of many herbal extracts with anti-inflammation effects. The current study is to find out the effects of JING SI HERBAL TEA in the treatment of this condition.

The patients will be divided into two groups by randomly assigned (estimated case number=100, experimental: control = 1: 1). The first group will receive two sachets of JING SI HERBAL TEA a day (one in the morning and one in the evening). The second group will receive two sachets of placebo a day (same way as group 1). The therapy will be three days after each intravesical installation therapies.

The outcome evaluations will use the American Urological Association Symptom Index and 12-Item Short Form Survey (SF-12). The baseline symptoms will be recorded before the first intravesical therapy. Patients will be asked to fill out the questionnaire every week (the same time for the next installation). Every other standard cancer therapies will not be will not be affected.

02

Conditions studied

  • Lower Urinary Tract Symptoms
  • Intravenous Drug Usage
  • Bladder Cancer
  • Herbal Interaction

Keywords

  • Intravesical installaion
  • Bladder cancer
  • Lower urinary tract symptoms
  • JING SI HERBAL TEA
03

Who can participate

Ages eligible
20 Years to 100 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Clinical diagnosis bladder cancer
  • Under intravesical installation therapy

Exclusion criteria

Exclusion Criteria:

  • Patients under 20 years old or greater than 100 years old
  • Women with pregnancy or breastfeeding plans
  • Bladder cancer are being treated in another hospital
  • Had admitted due to other disease in the past 3 months
  • Unable to understand the questionnaire
04

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Care provider)
Enrollment
100 participants (estimated)

Study arms

  • Experimental
    Experimental (group 1)

    This group will receive two sachets of JING SI HERBAL TEA a day (one in the morning and one in the evening).

    Dietary Supplement: JING SI HERBAL TEA

  • Placebo comparator
    Control (group 2)

    This group will receive two sachets of placebo a day (same way as group 1).

    Dietary Supplement: Placebo

Interventions

  • Dietary supplementJING SI HERBAL TEA

    JING SI HERBAL TEA is a food, contain with herbal extracts

  • Dietary supplementPlacebo

    Placebo will have the same appearance as JING SI HERBAL TEA

05

What researchers measure

Primary outcomes

  1. Urinary symptoms

    Change from baseline score at the following time will be recorded. The American urological association symptom index is a 7-item self report measure to assess the urinary symptoms. The score range from 0 to 35, the higher the severity.

    Time frame: The outcome evaluation will be at the following time points: 1 week, 2 weeks, 3 weeks, 4 weeks, 5 weeks and 6 weeks

Secondary outcomes

  1. Life quality

    Change from baseline score at the following time will be recorded. The 12-item shor form survey is a general health questionaire for life quality evaluation. The higher the value obtained, the more significant the impact on life.

    Time frame: The outcome evaluation will be at the following time points: 1 week, 2 weeks, 3 weeks, 4 weeks, 5 weeks and 6 weeks

06

Study locations

1 site
  • Buddhist Tzu Chi General Hospital, Taipei branch
    Taipei, Taiwan 231, Taiwan
07

References and documents

Individual participant data

Plan to share: No — The JING SI HERBAL TEA and Placebo are provided by the Tzu Chi Medical Foundation. We can not determining whether there are sufficient materials to provide the other participants

No publications or documents are linked to this record.

08

Registry details

Key details

Study ID
NCT05739071
Lead sponsor
Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation
Responsible party
Sponsor
First posted
Feb 22, 2023
Start date
Feb 22, 2023
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
Sep 11, 2025

Study contacts

Shu-Yu Wu, bachelor
study director · Taichung Tzu Chi Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion